4.4 Review

Pharmacologic Treatment of Pediatric Headaches

期刊

JAMA PEDIATRICS
卷 167, 期 3, 页码 250-258

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamapediatrics.2013.508

关键词

-

向作者/读者索取更多资源

Objective: To assess the effectiveness of prophylactic headache treatment in children and adolescents. Data Sources: PubMed, EMBASE, Cochrane Database of Clinical Trials, and bibliography of retrieved articles through August 11, 2012. Study Selection: Randomized trials of headache treatment among children and adolescents (<18 years old). Intervention: Any placebo-controlled trial or comparisons between 2 or more active medications. Main Outcome Measure: Number of headaches per month. Results: Among 21 included trials, there were 13 placebo-controlled and 10 active comparator trials (2 also included placebo). Twenty trials focused on episodic migraines and 1 on chronic daily headaches. Drugs more effective than placebo for episodic migraines (<15 headaches per month) included topiramate (difference in headaches per month, -0.71; 95% CI, -1.19 to -0.24) and trazodone ( 0.60; 95% CI, 1.09 to 0.11). Ineffective drugs included clonidine, flunarizine, pizotifen, propranolol, and valproate. A single trial of fluoxetine for chronic daily headaches found it ineffective. Patients given placebo experienced a significant (P=.03) decline in headaches, from 5.6 (95% CI, 4.52-6.77; Q= 8.14 [Cochran Q is a measure of the heterogeneity of the included studies]) to 2.9 headaches per month (95% CI, 1.66-4.08; Q= 4.72). Amongthe 10 active comparator trials, flunarizine was more effective than piracetam (difference in headaches per month, -2.20; 95% CI, -3.93 to -0.47) but no better than aspirin, dihydroergotamine, or propranolol. Propranolol was compared with valproate as well as behavioral treatment, and 2 studies compared different doses of topiramate; none of these trials showed significant differences. Conclusions: Topiramate and trazodone have limited evidence supporting efficacy for episodic migraines. Placebo was effective in reducing headaches. Other commonly used drugs have no evidence supporting their use in children and adolescents. More research is needed. JAMA Pediatr. 2013;167(3):250-258. Published online January 28, 2013. doi:10.1001/jamapediatrics.2013.508

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据